Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

191
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
191
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

171
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
171
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

229
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
229
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

225
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
225
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

242
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
242
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

401
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
401

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ten Years of Hydroxyurea for Ugandan Children with Sickle Cell Anemia.

The New England journal of medicine·2026
Same author

Persistent Splenomegaly Is Associated with Morbidity in Tanzanian Children with Sickle Cell Anemia: Secondary Analysis of the SPHERE Trial.

Acta haematologica·2026
Same author

Growth and puberty in African children with sickle cell anemia treated with hydroxyurea.

Blood advances·2026
Same author

Creative and Adaptive Solutions for Early Diagnosis of Sickle Cell Disease in Sub-Saharan Africa.

American journal of hematology·2026
Same author

Advancing Sickle Cell Disease Treatment in Sub-Saharan Africa: Challenges and Opportunities for Disease Modifying Therapies.

American journal of hematology·2026
Same author

Sickle Cell Disease in Sub-Saharan Africa: Progress and Potential.

American journal of hematology·2026
Same journal

Neurocognitive functioning of patients with sickle cell disease in low- and middle-income countries.

Blood global hematology·2026
Same journal

Hodgkin lymphoma treatment patterns and outcome disparities in low- and middle-income countries.

Blood global hematology·2026
Same journal

Immunogenomic profiles of HIV-associated classic Hodgkin lymphoma from Malawi.

Blood global hematology·2026
Same journal

Clinical integration of red cell genotyping in children with β-thalassemia major: a prospective observational study.

Blood global hematology·2026
Same journal

Urinary carbonic anhydrase 1 excretion is a marker of hemolysis-triggering conditions suitable for point-of-care testing.

Blood global hematology·2026
Same journal

Asian-type DEL among D-negative patients and donors in Malaysia can ease the demand for D-negative red cells and RhIG.

Blood global hematology·2026
See all related articles

Related Experiment Video

Updated: Jan 8, 2026

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.9K

Hydroxyurea to decrease stroke risk in children with sickle cell anemia: a systematic review and meta-analysis.

Emmanuela E Ambrose1, Paul Alikado Sabuni2, Don P Jason Iii3

  • 1Department of Pediatrics and Child Health, Catholic University of Health and Allied Sciences, Mwanza, Tanzania.

Blood Global Hematology
|December 24, 2025
PubMed
Summary
This summary is machine-generated.

Hydroxyurea effectively lowers stroke risk in children with sickle cell anemia (SCA) by reducing abnormal blood flow velocities. This treatment is a viable alternative to transfusions, especially in resource-limited areas.

More Related Videos

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

20.2K
Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases
11:08

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases

Published on: June 22, 2012

16.5K

Related Experiment Videos

Last Updated: Jan 8, 2026

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.9K
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

20.2K
Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases
11:08

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases

Published on: June 22, 2012

16.5K

Area of Science:

  • Pediatric Hematology
  • Neurology
  • Pharmacology

Background:

  • Sickle cell anemia (SCA) is an inherited disorder leading to stroke in children.
  • Transcranial Doppler (TCD) ultrasound assesses stroke risk in SCA patients.
  • Current stroke prevention includes transfusions, which have limitations in resource-limited settings.

Purpose of the Study:

  • To systematically review the effectiveness of hydroxyurea in reducing TCD velocities and stroke risk in children with SCA.
  • To clarify the effect size and duration of hydroxyurea's impact on TCD velocities.

Main Methods:

  • A systematic review of prospective clinical trials was conducted across five major medical databases.
  • Included trials enrolled children with SCA, used TCD screening, and collected serial TCD velocity and stroke incidence data during hydroxyurea therapy.
  • Data from 13 trials involving 592 participants were analyzed.

Main Results:

  • Hydroxyurea significantly decreased mean TCD velocities by -30 cm/s over 0.5 to 2.6 years, with normalization in most children.
  • Stroke incidence was low (0.52-1.92 per 100 patient-years) and occurred only in those with persistently high TCD values (>200 cm/s).
  • Hydroxyurea demonstrated effectiveness in reducing TCD velocities and associated stroke risk.

Conclusions:

  • Hydroxyurea is an effective strategy for mitigating stroke risk in pediatric SCA by reducing TCD velocities.
  • It presents a feasible alternative to blood transfusions, particularly beneficial in resource-limited healthcare settings.
  • Further research is warranted to optimize dosing, assess long-term safety, and evaluate comprehensive benefits across diverse populations.